Invivyd (IVVD) Return on Capital Employed (2021 - 2026)
Invivyd's (IVVD) quarterly Return on Capital Employed came in at 31.96% in Q4 2025, up 17926.0% YoY from N/an in Q4 2024, and up 64.23% on a QoQ basis from 89.35% in Q3 2025.
Invivyd (IVVD) Return on Capital Employed (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has 5 years of Return on Capital Employed data on file, last reported at 31.96% in Q4 2025.
- Quarterly Return on Capital Employed rose 17926.0% year-over-year to 31.96% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 31.96% (up 17926.0% YoY) and the FY2025 annual result came in at 32.87%, up 11783.0% from the prior year.
- Return on Capital Employed rose to 31.96% in Q4 2025, from 89.35% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 31.96% in Q4 2025 to a low of 257.32% in Q3 2024.
- A 5-year average of 109.97% and a median of 69.25% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 18868 bps — and 2025, when it soared 17926 bps.
- Tracing IVVD's Return on Capital Employed over 5 years: stood at 38.39% in 2021, then slumped by 71 bps to 65.46% in 2022, then tumbled by 61 bps to 105.45% in 2023, then plunged by 100 bps to 211.21% in 2024, then surged by 85 bps to 31.96% in 2025.
- The last three Return on Capital Employed figures came in at 31.96% (Q4 2025), 89.35% (Q3 2025), and 218.35% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | -38.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.95% |
| Dec 31, 2025 | -31.96% |
| Sep 30, 2025 | -89.35% |
| Jun 30, 2025 | -218.35% |
| Mar 31, 2025 | -220.35% |
| Dec 31, 2024 | -211.21% |
| Sep 30, 2024 | -257.32% |
| Jun 30, 2024 | -134.72% |
| Mar 31, 2024 | -118.17% |
| Dec 31, 2023 | -105.45% |
| Sep 30, 2023 | -68.64% |
| Jun 30, 2023 | -62.73% |
| Mar 31, 2023 | -54.05% |
| Dec 31, 2022 | -65.46% |
| Sep 30, 2022 | -69.25% |
| Jun 30, 2022 | -65.40% |
| Mar 31, 2022 | -58.65% |
| Dec 31, 2021 | -38.39% |